.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Colorcon
UBS
Accenture
Medtronic
Farmers Insurance
Chubb
Deloitte
Harvard Business School
Cipla

Generated: September 25, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Technetium-99m labeled peptides for imaging
Abstract:This invention relates to radiolabeled peptides and methods for producing such peptides. Specifically, the invention relates to peptides, methods and kits for making such peptides, and methods for using such peptides to image sites in a mammalian body labeled with technetium-99m (Tc-99m) via a radiolabel-binding moiety which forms a neutral complex with Tc-99m.
Inventor(s): Dean; Richard T. (Bedford, NH), Buttram; Scott (Derry, NH), McBride; William (Manchester, NH), Lister-James; John (Bedford, NH), Civitello; Edgar R. (Londonderry, NH)
Assignee: Diatide, Inc. (Londonderry, NH)
Filing Date:Apr 20, 1992
Application Number:07/871,282
Claims:1. A complex formed by reacting technetium-99m and a reducing agent with a reagent comprising

a) a peptide that specifically binds to a target in vivo; and

b) a radiolabel binding moiety covalently linked to the peptide; wherein the complex between said technetium-99m and said moiety is electrically neutral, avoiding interference by the complex with specific binding of the peptide to the target.

2. The complex of claim 1, wherein the reducing agent is selected from the group consisting of a dithionite ion, a stannous ion, and a ferrous ion.

3. A complex formed by labeling a reagent comprising

a) a peptide that specifically binds to a target in vivo; and

b) a radiolabel binding moiety covalently linked to the peptide; with technetium-99m by ligand exchange of a prereduced technetium-99m complex, wherein the complex between said technetium-99m and said moiety is electrically neutral, avoiding interference by the complex with specific binding of the pettide to the target.

4. The complex of claims 1, 2, or 3, wherein the moiety has a formula selected from the group consisting of: ##STR8## wherein each R is independently H, CH.sub.3 or C.sub.2 H.sub.5 ; each (pgp).sup.s is independently a thiol protecting group or H;

m, n and p are independently 2 or 3;

A=linear or cyclic lower alkyl, aryl, heterocyclyl, a combination thereof;

X=a bond covalently linking the moiety to the peptide;

and ##STR9## wherein each R is independently H, CH.sub.3 or C.sub.2 H.sub.5 ; m, n and p are independently 2 or 3;

A=linear or cyclic lower alkyl, aryl, heterocyclyl, a combination thereof;

V=H or --CO-X;

R'=H or X;

X=a bond covalently linking the moiety to the peptide;

and wherein when V=H, R'=peptide and when R'=H, V=--CO-peptide.

5. The complex of claims 1, 2, or 3, wherein the peptide is selected from the group consisting of:

formyl-MLF;

(VGVAPG).sub.3 amide;

(VPGVG).sub.4 amide;

RALVDTLKFVTQAEGAKamide (SEQ ID NO: 1);

RALVDTEFKVKQEAGAKamide (SEO ID NO: 2):

PLARITLPDFRLPEIAIPamide (SEQ ID NO: 3);

GQQHHLGGAKAGDV (SEQ ID NO: 4);

PLYKKIIKKLLES (SEQ ID NO: 5);

LRALVDTLKamide (SEQ ID NO: 6);

GGGLRALVDTLKamide (SEQ ID NO: 7);

GGGLRALVDTLKFVTQAEGAKamide (SEQ ID NO: 8);

GGGRALVDTLKALVDTLamide (SEQ ID NO: 9);

GHRPLDKKREEAPSLRPAPPPISGGGYR (SEQ ID NO: 10);

PSPSPIHPAHHKRDRRQamide (SEQ ID NO: 11);

GGGF.sub.D.Cpa.YW.sub.D KTFTamide; ##STR10## {SYNRGDSTC(S-maleimido)CH.sub.2 CH.sub.2 -}.sub.3 N]GCGGGLRALVDTLKamide (SEQ ID NO: 13);

GCYRALVDTLKFVTQAEGAKamide (SEQ ID NO: 14); and

GC(VGVAPG).sub.3 amide.

6. A method for imaging a site within a mammalian body comprising the steps of administering an effective diagnostic amount of the complex of claims 1, 2 or 3, and detecting the technetium-99m localized at the site.

7. A method for imaging a site within a mammalian body comprising the steps of administering an effective diagnostic amount of the complex of claim 5, and detecting the technetium-99m localized at the site.

8. An electrically neutral complex formed between technetium-99m and a radiolabel-binding moiety covalently linked to a peptide having specific binding properties, wherein interference with said properties by said complex is avoided.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Merck
Chinese Patent Office
Healthtrust
Deloitte
Chubb
Cantor Fitzgerald
US Department of Justice
Covington
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot